AETNA BETTER HEALTH® Coverage Policy/Guideline			
Name:	Diacomit (stiripentol)	Page:	1 of 2
Effective Date:	10/15/2025	Last Review Date:	9/2025
Applies to:	☒Illinois ☐Maryland ☐Michigan	☐Florida ☒Florida Kids ☐Virginia	☒New Jersey ☒Pennsylvania Kids ☐Kentucky PRMD

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Diacomit under the patient's prescription drug benefit.

Description:

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications[1]

Diacomit is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kilogram (kg) or more. There are no clinical data to support the use of Diacomit as monotherapy in Dravet syndrome.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Diacomit

Policy/Guideline:

Coverage Criteria

Seizures Associated with Dravet Syndrome[1]

Authorization of 12 months may be granted for treatment of seizures associated with Dravet syndrome in members 6 months of age and older.

Continuation of Therapy

Authorization of 12 months may be granted for continuation of treatment in members (including new members) 6 months of age or older requesting reauthorization for seizures associated with Dravet syndrome when the member has achieved or maintained a positive clinical response (e.g., decrease in seizure frequency).

Other

Member must be taking clobazam concurrently with another anti-seizure medication and cannot use the requested medication as monotherapy in Dravet syndrome.

Approval Duration and Quantity Restrictions:

Initial and Renewal Approval: 12 Months

Quantity Level Limits:

- Diacomit (stiripentol) 250 mg capsule: 360 per 30 days
- Diacomit (stiripentol) 500 mg capsule: 180 per 30 days
- Diacomit (stiripentol) 250 mg powder packet for oral suspension: 360 per 30 days
- Diacomit (stiripentol) 500 mg powder packet for oral suspension: 180 per 30 days

References:

1. Diacomit [package insert]. Gentilly, France: Biocodex; June 2024.